Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $229.02 million. The enterprise value is $100.48 million.
Important Dates
The last earnings date was Monday, March 9, 2026, before market open.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 97.87 million shares outstanding. The number of shares has increased by 7.78% in one year.
| Current Share Class | 97.87M |
| Shares Outstanding | 97.87M |
| Shares Change (YoY) | +7.78% |
| Shares Change (QoQ) | +7.95% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 51.94% |
| Float | 97.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.65 |
| Forward PS | 14.98 |
| PB Ratio | 8.39 |
| P/TBV Ratio | 8.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.66.
| Current Ratio | 3.54 |
| Quick Ratio | 3.50 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.10 |
Financial Efficiency
Return on equity (ROE) is -198.14% and return on invested capital (ROIC) is -57.84%.
| Return on Equity (ROE) | -198.14% |
| Return on Assets (ROA) | -23.51% |
| Return on Invested Capital (ROIC) | -57.84% |
| Return on Capital Employed (ROCE) | -70.81% |
| Weighted Average Cost of Capital (WACC) | 17.06% |
| Revenue Per Employee | $465,747 |
| Profits Per Employee | -$1.84M |
| Employee Count | 87 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.35% in the last 52 weeks. The beta is 2.19, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +68.35% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 54.04 |
| Average Volume (20 Days) | 1,984,783 |
Short Selling Information
The latest short interest is 11.89 million, so 12.15% of the outstanding shares have been sold short.
| Short Interest | 11.89M |
| Short Previous Month | 11.75M |
| Short % of Shares Out | 12.15% |
| Short % of Float | 12.19% |
| Short Ratio (days to cover) | 7.62 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $40.52 million and -$160.06 million in losses. Loss per share was -$1.80.
| Revenue | 40.52M |
| Gross Profit | -49.43M |
| Operating Income | -99.34M |
| Pretax Income | -160.06M |
| Net Income | -160.06M |
| EBITDA | -94.06M |
| EBIT | -99.34M |
| Loss Per Share | -$1.80 |
Full Income StatementBalance Sheet
The company has $146.65 million in cash and $18.10 million in debt, with a net cash position of $128.54 million or $1.31 per share.
| Cash & Cash Equivalents | 146.65M |
| Total Debt | 18.10M |
| Net Cash | 128.54M |
| Net Cash Per Share | $1.31 |
| Equity (Book Value) | 27.29M |
| Book Value Per Share | 0.28 |
| Working Capital | 117.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$165.24 million and capital expenditures -$607,000, giving a free cash flow of -$165.85 million.
| Operating Cash Flow | -165.24M |
| Capital Expenditures | -607,000 |
| Depreciation & Amortization | 5.28M |
| Net Borrowing | n/a |
| Free Cash Flow | -165.85M |
| FCF Per Share | -$1.69 |
Full Cash Flow StatementMargins
| Gross Margin | -122.00% |
| Operating Margin | -245.15% |
| Pretax Margin | -395.01% |
| Profit Margin | n/a |
| EBITDA Margin | -232.13% |
| EBIT Margin | -245.15% |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.78% |
| Shareholder Yield | -7.78% |
| Earnings Yield | -69.89% |
| FCF Yield | -72.42% |
Analyst Forecast
The average price target for Editas Medicine is $4.92, which is 110.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.92 |
| Price Target Difference | 110.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -10.88% |
| EPS Growth Forecast (5Y) | -11.87% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -12.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.27 |
| Piotroski F-Score | 2 |
